Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia

Gene Therapy

Volumn 9, Issue 24, 2002, Pages 1682-1692

  Ahn, J D ^a   Morishita, R ^b   Kaneda, Y ^b   Kim, H S ^c   Chang, Y C ^c   Lee, K U ^d   Park, J Y ^d   Lee, H W ^e   Kim, Y H ^a   Lee, I K ^c  

^a Kyungpook National University   (South Korea)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c Keimyung University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Yeungnam University College of Medicine   (South Korea)

Author keywords

Dumbbell; E2F decoy; Neointimal formation; Non viral vector; VSMC proliferation

Indexed keywords

CIS ACTING ELEMENT; DOUBLE STRANDED DNA; GLUCOSE; NUCLEASE; OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; TRANSCRIPTION FACTOR E2F;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; BINDING SITE; BLOOD VESSEL INJURY; CELL CYCLE; CELL PROLIFERATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DNA TRANSFECTION; DOSE RESPONSE; DRUG HALF LIFE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATOR GENE; REGULATORY MECHANISM; REVIEW; SERUM; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; BINDING SITES; CAROTID STENOSIS; CELL CYCLE PROTEINS; CELL DIVISION; CELLS, CULTURED; CYCLIN A; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION; GENE THERAPY; HUMANS; HYPERPLASIA; MALE; MUSCLE, SMOOTH, VASCULAR; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; TRANSFECTION; TUNICA INTIMA;

ANIMALIA;

EID: 0036956811     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301849     Document Type: Review

References (34)

1. Scholer HR, Gruss P. Specific interaction between enhancer-containing molecules and cellular components. Cell 1984; 36: 403-411.
2. Cereghini S, Blumenfeld M, Yaniv M. A liver-specific factor essential for albumin transcription differs between differentiated and dedifferentiated rat hepatoma cells. Genes Dee 1988; 2: 957-974.
3. Berkowitz LA, Riabowol KT, Gilman MZ. Multiple sequence elements of a single functional class are required for cyclic AMP responsiveness of the mouse c-fos promoter. Mol Cell Biol 1989; 9: 4272-4281.
4. Tanaka H et al. Sequence-specific interaction of alpha-beta-anomeric double-stranded DNA with the p50 subunit of NF kappa B: application to the decoy approach. Nucleic Acids Res 1994; 22: 3069-3074.
5. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990; 250: 997-1000.
6. Clusel C et al. Ex vivo regulation of specific gene expression by nanomolar concentration of double-stranded dumbbell oligonucleotides. Nucleic Acids Res 1993; 21: 3405-3411.
7. Lim CS et al. Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys. Nucleic Acids Res 1997; 25: 575-581.
8. Hosoya T et al. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999; 461: 136-140.
9. Khaled Z et al. Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligonucleotides. Nucleic Acids Res 1996; 24: 737-775.
10. Gao WY et al. Phosphorothioate oligodeoxynucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1992; 41: 223-229.
11. Brown DA et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269: 26 801-26 805.
12. Burgess TL et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995; 92: 4051-4055.
13. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol 1995; 25: 516-520.
14. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after injury. Lab Invest 1983; 49: 208-215.
15. Liu MW, Roubin Gs, King SB III. Restenosis after coronary angioplasty. Circulation 1989; 79: 1374-1387.
16. Pagano M et al. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11: 961-971.
17. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71: 1286-1290.
18. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358: 259-261.
19. Pagano MG, Draetta G, Durr J. Association of cdk2 kinase with the transcription factor E2F during S phase. Science 1992; 255: 1144-1147.
20. Rosenblatt J, Gu Y, Morgan DO. Human cyclin-dependent kinase 2 is activated during S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA 1992; 89: 2824-2828.
21. Simons M et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-73.
22. Morishita R et al. Intimal hyperplasia after vascular injury is inhibiter by antisense cdk 2 kinase oligonucleotides. J Clin Invest 1994; 93:1458-1464.
23. Morishita R et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478.
24. Morishita R et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-5859.
25. Morishita R et al. In vivo transfection of cis element "decoy" against NFkB binding site prevented myocardial infarction as gene therapy. Nat Med 1997; 3: 894-899.
26. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
27. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor includes DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15: 4215-4224.
28. Chu BC, Orgel LE. The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res 1992; 20: 5857-5858.
29. Abe T et al. Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides. FEBS Lett 1998; 425: 91-96.
30. Marcus-Sekure CJ. Techniques for using antisense oligodeoxynucleotides to study gene expression. Anal Biochem 1988; 172: 289-295.
31. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988; 48: 2659-2668.
32. Ahn JD et al. Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor (PAI-1) gene expression in cultured human vascular smooth muscle cells. Diabetologia 2001; 44: 713-720.
33. Natarajan R et al. Angiotensin II signaling in vascular smooth muscle cells under high glucose conditions. Hypertension 1999; 33: 378-384.
34. Yasunari K et al. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. Circ Res 1997; 81: 953-962.